Diorasis Therapeutics Email Formats

Biotechnology Research • Watertown, Massachusetts, United States • 1-10 Employees

Key Contact at Diorasis Therapeutics

Subhro Guhathakurta

Vice President of Research & Development

Company overview

Headquarters	134 Coolidge Ave, Watertown, Massachusetts 02472, US
Website	diorasistherapeutics.com
NAICS	541714
Founded	2022
Employees	1-10
Socials

About Diorasis Therapeutics

Diorasis Therapeutics is a preclinical-stage company developing gene therapy for glaucoma. Our disease-modifying gene agnostic single intracameral injection gene therapy produces tissue of modified plasminogen activator (tPA) that normalizes trabecular meshwork outflow and IOP. Demonstrated significant efficacy : Mice glaucoma model: outflow facility returned to normal, and IOP decreased to normal level after a single intracameral tPA GTx injection Sheep glaucoma model: a single intracameral tPA-producing GTx injection dramatically decreased IOP to normal levels lasting until the end of 6 weeks experiment without any observed safety concerns Normal mouse: no decrease in IOP (hypotony) after intracameral tPA GTx injection Currently, we are conducting tox and IND-enabling studies to file IND

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Vice President

Funding Data

Diorasis Therapeutics has never raised funding before.

Frequently asked questions

Diorasis Therapeutics is located in Watertown, Massachusetts, US.

Diorasis Therapeutics was founded in 2022, making it 4 years old. The company has established itself as a significant player in its industry over this time.

Diorasis Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Diorasis Therapeutics

Subhro Guhathakurta

Vice President of Research & Development

4.8

40,000 users